by Peter Ciszewski | May 27, 2021
Quinn Dinh, MD, Vice President of Medical Affairs at Horizon Therapeutics, discusses areas of research Horizon is focusing on in regard to inebilizumab-cdon (uplizna) and neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare central nervous disorder...
by Peter Ciszewski | May 26, 2021
Julia Jenkins, Executive Director at Everylife Foundation, and Dylan Simon, Newborn Screening and Diagnostics Policy Manager at Everylife Foundation, discuss how the organization goes about encouraging different states to include the diseases listed in the...
by Peter Ciszewski | May 25, 2021
Louise Vetter, President and CEO of the Huntington’s Disease Society of America, discusses the unique relationship Huntington disease families and researchers have. Huntington disease is an inherited, neurodegenerative disorder that usually begins to be...
by Peter Ciszewski | May 24, 2021
Quinn Dinh, MD, Vice President of Medical Affairs at Horizon Therapeutics, discusses inebilizumab-cdon (uplizna), the first and only FDA-approved B-cell depleter for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis...
by Peter Ciszewski | May 20, 2021
Bruce Cree, MD, PhD, MAS, Associate Professor of Clinical Neurology in the Department of Neurology at the University of California San Francisco, discusses which healthcare professional is most likely to diagnose patients with neuromyelitis optica spectrum...
